Voya Investment Management LLC Sells 92,508 Shares of Amicus Therapeutics, Inc. $FOLD

Voya Investment Management LLC reduced its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 13.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 583,845 shares of the biopharmaceutical company’s stock after selling 92,508 shares during the quarter. Voya Investment Management LLC owned approximately 0.19% of Amicus Therapeutics worth $4,764,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Strs Ohio bought a new position in shares of Amicus Therapeutics during the first quarter valued at $30,000. PNC Financial Services Group Inc. raised its holdings in shares of Amicus Therapeutics by 211.4% in the first quarter. PNC Financial Services Group Inc. now owns 5,151 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 3,497 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S bought a new position in shares of Amicus Therapeutics in the first quarter valued at about $53,000. GF Fund Management CO. LTD. bought a new position in shares of Amicus Therapeutics in the fourth quarter valued at about $59,000. Finally, GAMMA Investing LLC raised its holdings in shares of Amicus Therapeutics by 1,610.8% in the first quarter. GAMMA Investing LLC now owns 7,442 shares of the biopharmaceutical company’s stock valued at $61,000 after buying an additional 7,007 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on FOLD shares. Wall Street Zen cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, August 30th. Morgan Stanley raised Amicus Therapeutics from an “equal weight” rating to an “overweight” rating in a report on Thursday, July 17th. Finally, Needham & Company LLC upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a research report on Thursday. Eight analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, Amicus Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $15.78.

Amicus Therapeutics Price Performance

Shares of FOLD opened at $8.48 on Friday. The company has a debt-to-equity ratio of 1.92, a quick ratio of 2.29 and a current ratio of 3.21. The stock has a 50 day simple moving average of $7.09 and a 200 day simple moving average of $6.98. Amicus Therapeutics, Inc. has a 52-week low of $5.51 and a 52-week high of $12.65. The firm has a market capitalization of $2.61 billion, a PE ratio of -70.66 and a beta of 0.55.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.